Akari Therapeutics

134 articles with Akari Therapeutics

• Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

  3/30/2023

  Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that it has entered into definitive agreements with certain institutional investors and accredited investors.

• Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

  3/29/2023

  Akari Therapeutics, Plc announced regulatory authorities in Poland and the U.K. have approved amendments to the company’s Investigational Medicinal Product Dossier and Clinical Trial Authorisation, respectively, for clinical use of the third-generation drug substance manufacturing process that increases the final yield of nomacopan by at least 5-fold.

• Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

  2/21/2023

  Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

• Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

  2/15/2023

  Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced updates on progress in the pre-clinical development program for long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

• Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults

  2/13/2023

  Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the Phase 3 clinical trial of nomacopan in pediatric patients with hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) is moving into Part B sooner than expected and the company is beginning the planning and design for the pivotal study in pediatric patients over 2 years of age.

• Akari Therapeutics to Present at Biotech Showcase™ 2023

  1/4/2023

  Akari Therapeutics, Plc announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET.

• Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

  12/1/2022

  Akari Therapeutics, Plc announced the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022.

• Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

  11/22/2022

  Akari Therapeutics, Plc today announced that the company will participate in the Ophthalmology Day at BTIG on November 29, 2022.

• 

  Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More

  11/11/2022

  While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.  

• Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

  11/10/2022

  Akari Therapeutics, Plc announced the U.S. Food and Drug Administration has granted the Rare Pediatric Disease Designation to nomacopan for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.

• Akari Therapeutics to Participate in the 2022 Jefferies London Healthcare Conference

  11/9/2022

  Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that the company will participate in the Jefferies London Healthcare Conference scheduled to take place November 15-17, 2022.

• Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer

  11/8/2022

  Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of John F. Neylan, III, MD, as Executive Vice President, Chief Medical Officer, effective today.

• Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference

  10/31/2022

  Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Sidoti November Virtual Micro-Cap Conference on November 9, 2022.

• Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

  10/28/2022

  Akari Therapeutics, Plc (Nasdaq: AKTX) today announced that Akari received a letter from Nasdaq Listing Qualifications indicating that Akari is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

• Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

  9/27/2022

  Akari Therapeutics, Plc today announced financial results for the quarter ended June 30, 2022, as well as pre-clinical and clinical progress on nomacopan and long-acting PAS-nomacopan.

• Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

  9/22/2022

  Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Cantor Oncology & HemOnc Conference on September 28, 2022.

• Akari Therapeutics Announces $12.75 Million Registered Direct Offering

  9/12/2022

  Akari Therapeutics, Plc announced it has entered into definitive agreements with healthcare-focused institutional investors alongside participation from certain existing investors, including the Akari Executive Chairman of the Board of Directors, Dr. Ray Prudo, for the purchase and sale of 15,000,000 Akari American Depository Shares at a purchase price of $0.85 per ADS.

• Akari Therapeutics Narrows Pipeline Focus

  8/1/2022

  Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that it is prioritizing two pipeline programs.

• Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

  7/28/2022

  Akari Therapeutics, Plc today announced positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy (GA) in dry age-related macular degeneration (dAMD).

• Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

  7/20/2022

  Akari Therapeutics, Plc announced financial results for the quarter ended March 31, 2022, as well as research and development progress on nomacopan and long-acting PAS-nomacopan.